Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SNPX 
Synaptogenix Inc (SNPX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SNPX (2-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $14
1 Year Target Price $14
| 0 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 65.44% | Avg. Invested days 29 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.91M USD | Price to earnings Ratio - | 1Y Target Price 14 |
Price to earnings Ratio - | 1Y Target Price 14 | ||
Volume (30-day avg) 1 | Beta 1.3 | 52 Weeks Range 1.84 - 11.98 | Updated Date 08/15/2025 |
52 Weeks Range 1.84 - 11.98 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.46 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.29% | Return on Equity (TTM) -83.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 7857896 | Price to Sales(TTM) - |
Enterprise Value 7857896 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.28 | Shares Outstanding 1389820 | Shares Floating 1380698 |
Shares Outstanding 1389820 | Shares Floating 1380698 | ||
Percent Insiders 1.9 | Percent Institutions 3.76 |
Upturn AI SWOT
Synaptogenix Inc
Company Overview
History and Background
Synaptogenix Inc. is a biopharmaceutical company focused on developing therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. Founded to address unmet medical needs in this area, the company's primary focus is on bryostatin-1 and its potential to enhance synaptic function.
Core Business Areas
- Drug Development: Focuses on the research, development, and clinical trials of bryostatin-1 for treating neurodegenerative diseases, primarily Alzheimer's disease.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of bryostatin-1 in patients with Alzheimer's disease and other cognitive impairments.
- Intellectual Property: Manages and expands its patent portfolio related to bryostatin-1 and its applications.
Leadership and Structure
The leadership team consists of experienced professionals in drug development, clinical research, and business management. The company is structured to support its research and development activities, with a focus on clinical trials and regulatory approvals.
Top Products and Market Share
Key Offerings
- Bryostatin-1: Synaptogenix's lead drug candidate, bryostatin-1, is being developed as a treatment for Alzheimer's disease. Market share data is not directly available, as the drug is still in clinical trials. Competitors include companies developing alternative Alzheimer's treatments, such as Biogen (Aduhelm), Eisai (Leqembi), and Eli Lilly (Donanemab).
Market Dynamics
Industry Overview
The biopharmaceutical industry for neurodegenerative diseases is highly competitive and rapidly evolving, with a significant unmet medical need for effective treatments, especially for Alzheimer's disease.
Positioning
Synaptogenix is positioned as a company focused on developing novel therapeutics for Alzheimer's disease, with bryostatin-1 as its primary asset. Its competitive advantage lies in the unique mechanism of action of bryostatin-1, which aims to enhance synaptic function.
Total Addressable Market (TAM)
The global Alzheimer's disease market is estimated to be worth billions of dollars. Synaptogenix aims to capture a portion of this market by offering a potentially disease-modifying treatment for Alzheimer's.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (bryostatin-1)
- Experienced management team
- Focused on a significant unmet medical need
Weaknesses
- Single product pipeline (bryostatin-1)
- High dependence on clinical trial outcomes
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Positive clinical trial results for bryostatin-1
- Partnerships with larger pharmaceutical companies
- Expansion of bryostatin-1's applications to other neurodegenerative diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent expiration
Competitors and Market Share
Key Competitors
- Biogen (BIIB)
- Eisai (ESALY)
- Eli Lilly (LLY)
Competitive Landscape
Synaptogenix is a smaller player compared to established pharmaceutical giants like Biogen, Eisai, and Eli Lilly. Its success hinges on the unique mechanism and efficacy of bryostatin-1.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by clinical trial progress and funding secured.
Future Projections: Future growth depends on the successful development and commercialization of bryostatin-1.
Recent Initiatives: Recent initiatives include conducting clinical trials of bryostatin-1 and seeking partnerships to fund further development.
Summary
Synaptogenix is a high-risk, high-reward biopharmaceutical company with a focus on developing bryostatin-1 for Alzheimer's disease. The company's success depends heavily on the outcome of its clinical trials. It faces strong competition from larger, well-established pharmaceutical companies and needs to secure further funding and partnerships to advance its pipeline. Positive trial results and strategic collaborations are crucial for its future growth and sustainability.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share estimates are approximate and may vary depending on the source. Consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Synaptogenix Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2020-12-08 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 4 | Website https://www.synaptogen.com |
Full time employees 4 | Website https://www.synaptogen.com | ||
TAO Synergies Inc. operates as a biopharmaceutical company. The company is primarily focused on developing a product platform based upon Bryostatin-1, for the treatment of Alzheimer's disease (AD), which is in the clinical testing stage. It is also evaluating potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis (MS), and Niemann-Pick Type C disease, which have undergone pre-clinical testing. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.n as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.